# Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

> **NCT04919109** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Codagenix, Inc** · enrollment: 51 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** CodaVax-RSV
- **BIOLOGICAL:** Normal Saline

## Key facts

- **NCT ID:** NCT04919109
- **Lead sponsor:** Codagenix, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-28
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-08-27
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04919109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04919109, "Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04919109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*